Table 1.

Competitive environment

Drugs or approaches	Company group	Development stage (trial name)	Mechanism of action
Nimodipine	Bayer	HIT 4	Calcium channel blocker
SNX-111	Neurox/Parke Davis	I/II (terminated due to high mortality)	N-type calcium channel blocker
Corticosteroids	Pharmacia/Upjohn, Pfizer	CRASH	Anti oxidative effect
Darbepoetin alfa	Amgen	II	Erythropoiesis and neuroprotection
Dexanabinol	Pharmos	III	NMDA receptor antagonist
Recombinant factor VIIa	NovoSeven	I	Haemostatic effect
Methylphenidate (Ritalin)	Novartis	IV	Dopamine antagonist
Amantadine	Banner Pharmacaps	II	Dopaminergic agonist
Anatibant	Solvay	II	Bradykinin B2 antagonist
Progesterone	Emory University Investigational Drug Service	II (ProTECT)	Multiple effects (anti-inflammatory, anti-oxidative, anti- apoptotic)
Rosuvastatin(Crestor)	AstraZeneca	I	β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitor
EPO	Amgen	III	Erythropoiesis and neuroprotection